{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:18:08Z","timestamp":1782389888666,"version":"3.54.5"},"reference-count":57,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":37,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.autrev.2024.103590","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T01:18:56Z","timestamp":1723079936000},"page":"103590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The pipeline of immunomodulatory therapies in polymyalgia rheumatica and giant cell arteritis: A systematic review of clinical trials"],"prefix":"10.1016","volume":"23","author":[{"given":"Lou","family":"Kawka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Chevet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Carvajal Alegria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Felten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2024.103590_bb0005","article-title":"Giant cell arteritis","volume":"365","author":"Lazarewicz","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2024.103590_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102670","article-title":"The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle","volume":"19","author":"Carvajal Alegria","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103590_bb0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10067-021-05819-z","article-title":"Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis","volume":"41","author":"Floris","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2024.103590_bb0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/cells13030267","article-title":"Giant cell arteritis: advances in understanding pathogenesis and implications for clinical practice","volume":"13","author":"Paroli","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.autrev.2024.103590_bb0025","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.autrev.2018.02.011","article-title":"The 2018 pipeline of targeted therapies under clinical development for systemic lupus erythematosus: a systematic review of trials","volume":"17","author":"Felten","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103590_bb0030","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.autrev.2018.12.008","article-title":"The pipeline of targeted therapies under clinical development for primary Sj\u00f6gren\u2019s syndrome: a systematic review of trials","volume":"18","author":"Felten","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2024.103590_bb0035","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20959971","article-title":"Immunosuppressive agents for rheumatoid arthritis: a systematic review of clinical trials and their current development stage","volume":"12","author":"Blaess","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.autrev.2024.103590_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003279","article-title":"The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials","volume":"9","author":"Denis","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2024.103590_bb0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103590_bb0050","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/ard.2003.011379","article-title":"A disease activity score for polymyalgia rheumatica","volume":"63","author":"Leeb","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103590_bb0055","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","article-title":"Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial","volume":"141","author":"Caporali","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2024.103590_bb0060","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.55.4.218","article-title":"Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?","volume":"55","author":"van der Veen","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103590_bb0065","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s13063-022-06263-3","article-title":"PolyMyalgia Rheumatica treatment with methotrexate in optimal dose in an early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial","volume":"23","author":"Marsman","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.autrev.2024.103590_bb0070","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","article-title":"Sarilumab for relapse of polymyalgia Rheumatica during glucocorticoid taper","volume":"389","author":"Spiera","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103590_bb0075","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.39740","article-title":"Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia Rheumatica","volume":"68","author":"Lally","year":"2016","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.autrev.2024.103590_bb0080","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","article-title":"Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study","volume":"75","author":"Devauchelle-Pensec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103590_bb0085","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1111\/1756-185X.13723","article-title":"Tocilizumab monotherapy for polymyalgia rheumatica: a prospective, single-center, open-label study","volume":"22","author":"Chino","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103590_bb0090","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial","volume":"81","author":"Bonelli","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103590_bb0095","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.2022.15459","article-title":"Effect of tocilizumab on disease activity in patients with active polymyalgia Rheumatica receiving glucocorticoid therapy: a randomized clinical trial","volume":"328","author":"Devauchelle-Pensec","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2024.103590_bb0100","doi-asserted-by":"crossref","first-page":"R176","DOI":"10.1186\/ar3140","article-title":"Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial","volume":"12","author":"Kreiner","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2024.103590_bb0105","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","article-title":"Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial","volume":"146","author":"Salvarani","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2024.103590_bb0110","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(23)00032-2","article-title":"1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial","volume":"5","author":"Bolhuis","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2024.103590_bb0115","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.1016\/S2665-9913(23)00246-1","article-title":"Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial","volume":"5","author":"Saraux","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2024.103590_bb0120","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/ard-2022-223562","article-title":"Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study","volume":"82","author":"Zhang","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103590_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004249","article-title":"Efficacy and safety of Tofacitinib in patients with polymyalgia Rheumatica (EAST PMR): an open-label randomized controlled trial","volume":"20","author":"Ma","year":"2023","journal-title":"PLoS Med"},{"key":"10.1016\/j.autrev.2024.103590_bb0130","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2024.103590_bb0135","first-page":"495","article-title":"A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2024.103590_bb0140","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103590_bb0145","unstructured":"Adding hydroxychloroquine to prednisone does not improve the outcome in giant cell arteritis: a double blind randomized controlled trial Cochrane Library n.d. doi:https:\/\/doi.org\/10.1002\/central\/CN-01749524."},{"key":"10.1016\/j.autrev.2024.103590_bb0150","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2024.103590_bb0155","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejim.2018.06.008","article-title":"Tocilizumab as an add-on therapy to glucocorticoids during the first 3\u00a0months of treatment of Giant cell arteritis: a prospective study","volume":"57","author":"Samson","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.autrev.2024.103590_bb0160","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1016\/S2665-9913(21)00152-1","article-title":"Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study","volume":"3","author":"Christ","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2024.103590_bb0165","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in Giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2024.103590_bb0170","doi-asserted-by":"crossref","first-page":"e736","DOI":"10.1016\/S2665-9913(23)00265-5","article-title":"Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study","volume":"5","author":"Unizony","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2024.103590_bb0175","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13075-023-03177-6","article-title":"A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis","volume":"25","author":"Schmidt","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2024.103590_bb0180","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40744-020-00227-2","article-title":"A multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Sirukumab in the treatment of Giant cell arteritis","volume":"7","author":"Schmidt","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.autrev.2024.103590_bb0185","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2024.103590_bb0190","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","article-title":"Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial","volume":"73","author":"Seror","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103590_bb0195","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Mart\u00ednez-Taboada","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103590_bb0200","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2665-9913(23)00101-7","article-title":"Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Venhoff","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2024.103590_bb0205","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/acr.24200","article-title":"Ustekinumab for the treatment of Giant cell arteritis","volume":"73","author":"Matza","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2024.103590_bb0210","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A randomized, double-blind trial of Abatacept (CTLA-4Ig) for the treatment of Giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103590_bb0215","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","article-title":"Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"81","author":"Cid","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103590_bb0220","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/annrheumdis-2021-221961","article-title":"Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study","volume":"81","author":"Koster","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103590_bb0225","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20969261","article-title":"Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis","volume":"12","author":"Petitdemange","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.autrev.2024.103590_bb0230","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/art.34327","article-title":"Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis","volume":"64","author":"Terrier","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103590_bb0235","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-121-7-199410010-00003","article-title":"Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis","volume":"121","author":"Weyand","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2024.103590_bb0240","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1136\/annrheumdis-2021-220873","article-title":"Blocking GM-CSF receptor \u03b1 with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis","volume":"81","author":"Corbera-Bellalta","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103590_bb0245","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2024.103590_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2024.105730","article-title":"Recommendations of the French Society of Rheumatology for the management in current practice of patients with polymyalgia Rheumatica","author":"Wendling","year":"2024","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2024.103590_bb0255","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103590_bb0260","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103590_bb0265","doi-asserted-by":"crossref","first-page":"1199059","DOI":"10.3389\/fimmu.2023.1199059","article-title":"The IL-17 pathway as a target in giant cell arteritis","volume":"14","author":"Zeisbrich","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2024.103590_bb0270","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/rheumatology\/kex507","article-title":"Secukinumab for the maintenance of glucocorticoid-free remission in a patient with giant cell arteritis and psoriatic arthritis","volume":"57","author":"Rotar","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2024.103590_bb0275","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1161\/CIRCULATIONAHA.117.030423","article-title":"Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel Vasculitis","volume":"137","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.autrev.2024.103590_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102796","article-title":"Interferon signature in giant cell arteritis aortitis","volume":"127","author":"Vieira","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2024.103590_bb0285","first-page":"13","article-title":"Perspectives of JAK inhibitors for large vessel Vasculitis","author":"Watanabe","year":"2022","journal-title":"Front Immunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224000818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224000818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T16:52:30Z","timestamp":1725468750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224000818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":57,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1568997224000818"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103590","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pipeline of immunomodulatory therapies in polymyalgia rheumatica and giant cell arteritis: A systematic review of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103590","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103590"}}